Bridging the Gap - On Easing the Transition from Arab Secondary to Western Third Level Learning.

Learning and achievement issues among Foundation Year (FY) students at the Royal College of Surgeons (RCSI) Bahrain have been responded to by the Language and Culture Unit to address the educational problems that have arisen as a direct consequence of the differences in skills students have on leaving secondary school and the skills that are required at third level institutions. The findings of the study assess the extent to which an integration of sustainable development into course objectives and learning outcomes takes place and how the content of the course responds to specific students’ needs. The research consists of an in-depth quantitative and qualitative case study that evaluates the extent to which the course enables the transition from a secondary to a third level institution and teaches the students the skills required to ‘survive’ at a westerntype university. In support of our claim, the results from this case study will be presented and implications of a more general relevance will be suggested. Our model of an academic skills intervention programme can be applied to other higher education institutions where issues of transition from secondary to third level learning may be problematic

Bridging the Gap: A Program to Enhance Medical Students\u27 Learning Experience in the Foundation Year

Objective: To evaluate students’ perceptions of the intervention program based on small group teaching, regular continuous assessment, science-based tailored study skills program and recorded attendance on students’ enhanced learning experience in the first year of study in an outcome-based medical course. Design: Descriptive study. Setting: RCSI Bahrain. Method: A Twenty-seven-item questionnaire was administered to foundation year students at the Royal College of Surgeons in Ireland – Medical University of Bahrain (RCSI Bahrain) after the completion of the first semester to explore whether these interventions enriched the students’ learning experience or not. Comparisons of pass rates in all modules over the four years were also included. Students’ perceptions of the academic study skills course were collected through a questionnaire activity (version 2007120102) via the Virtual Learning Environment (VLE). Result: The results suggest that local adaptations of undergraduate programs may lead to pedagogical expertise that contribute to enhanced learning experience of students and better integration of pre-university and third-level courses. The majority of questionnaire items were rated positively and the comparison of pass rates showed the highest results in the year the intervention was implemented. Conclusion: Making local adaptations to medical programs without changing the core curriculum can mark good academic practice. Considering specific socio-cultural frameworks of students may lead to improvements in the delivery of programs in universities

Additional file 3: of Analysis of psychometric properties of the modified SETQ tool in undergraduate medical education

Master sheet data. (XLS 596 kb

Time till viral clearance of Severe Acute Respiratory Syndrome Coronavirus 2 is similar for asymptomatic and non-critically symptomatic individuals.

Despite the modeled estimations of the burden of asymptomatic spread, the duration of viral positivity and infectiousness of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains understudied. The objective of the present study was to estimate and compare the time till viral clearance of SARS-CoV-2 in asymptomatic and non-critical symptomatic individuals. We studied 184 SARS-CoV-2-positive participants, of whom 145 were asymptomatic. Our analysis uncovered that time till viral negativity is similar for subclinical [median time till viral clearance: 11 days, interquartile range (IQR): 8, 14] and overt infections (median: 11 days, IQR: 9, 14) after controlling for age and sex. This has implications in understanding the period of infectivity for SARS-CoV-2 in order to plan adequate public health measures to control the community spread

The prevalence of asymptomatic and symptomatic COVID-19 in a cohort of quarantined subjects

Background: The frequency of asymptomatic SARS-CoV-2 infection with viral spread is unclear. Asymptomatic SARS-CoV-2 infection development and progression was investigated in subjects undergoing mandatory quarantine on airport arrival.Methods: 2714 subjects were tested for SARS-CoV-2 and all were quarantined for 2 weeks. Viral retesting was undertaken on symptom development and routinely at 14 days if asymptomatic. Asymptomatic, positive patients underwent viral testing every 2 days to determine viral clearance.Results: 188/2714 (6.9%) patients became SARS-CoV-2 positive. On arrival, 136/188 tested positive, with 44/188 (23.4%) symptomatic and 92/188 (48.9%) asymptomatic. All 92 patients remained asymptomatic and were retested every 2 days until viral clearance. 2526 quarantined subjects remained virus free at 14 days. Viral clearance did not differ between symptomatic and asymptomatic patients (12.6 ± 1.0 days and 12.1 ± 0.4 days, respectively). Of the 52/188 (27.7%) testing negative on arrival, 27/52 subsequently became positive and developed symptoms 2-13 days after arrival. 25/188 (13.3%) remained asymptomatic and tested positive at day 14, with viral testing undertaken every 2 days in these subjects; of these, 24 remained asymptomatic, with viral clearance at 9.4 ± 0.7 days - less than for those who were asymptomatic on arrival (p Conclusion: Asymptomatic patients with COVID-19 were more prevalent than those exhibiting symptoms, and are an infection reservoir.</p

COVID-19 and sickle cell disease in Bahrain

Introduction: Coronavirus disease 2019 (COVID-19) is caused by a newly identified strain of the coronavirus family that has been shown to affect the hemoglobin beta chain, the same chain that has sickle cell disease (SCD) mutation. This study was undertaken to see if COVID-19 infection increased disease severity in patients with SCD.Methods: Mass screening of the Bahraini population was undertaken between February and April 2020.Results: A total of 38,092 Bahraini people were tested for COVID-19 during this period; 378 (1%) were SCD patients. Six patients with SCD had COVID-19 (1.6%): three remained asymptomatic, two had mild symptoms and one required oxygen therapy. The SCD patients had a similar average length of stay when compared with non-SCD COVID-19 patients (10.7 days).Conclusion: The infection rate, clinical course and viral clearance seen for the SCD patients with COVID-19 were no different to those without SCD.</p

Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease

Convalescent plasma (CP) therapy in COVID-19 disease may improve clinical outcome in severe disease. This pilot study was undertaken to inform feasibility and safety of further definitive studies. This was a prospective, interventional and randomized open label pilot trial in patients with severe COVID-19. Twenty COVID-19 patients received two 200 ml transfusions of convalescent patient CP over 24-h compared with 20 who received standard of care. The primary outcome was the requirement for ventilation (non-invasive or mechanical ventilation). The secondary outcomes were biochemical parameters and mortality at 28 days. The CP group were a higher risk group with higher ferritin levels (p < 0.05) though respiratory indices did not differ. The primary outcome measure was required in 6 controls and 4 patients on CP (risk ratio 0.67, 95% CI 0.22–2.0, p = 0.72); mean time on ventilation (NIV or MV) did not differ. There were no differences in secondary measures at the end of the study. Two patients died in the control and one patient in the CP arm. There were no significant differences in the primary or secondary outcome measures between CP and standard therapy, although a larger definitive study is needed for confirmation. However, the study did show that CP therapy appears to be safe in hospitalized COVID-19 patients with hypoxia. Clinical trials registration NCT04356534: 22/04/2020

Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease

Favipiravir has antiviral activity against influenza, West Nile virus, and yellow fever virus and against flaviviruses. The objective of this pilot study was to compare three arms: favipiravir; hydroxychloroquine; standard care (no specific SARS-CoV-2 treatment) only, in symptomatic patients infected by SARS-CoV-2 in an open-labelled randomized clinical trial. The trial was registered with Bahrain National Taskforce for Combatting COVID-19 on the 7th of May 2020 (registration code: NCT04387760). 150 symptomatic patients with COVID-19 disease were randomized into one of three arms: favipiravir, hydroxychloroquine, or standard care only. The primary outcome was the clinical scale at the end of study follow up (day 14 or on discharge/death) based on a points scale. The secondary outcomes were viral clearance, biochemical parameter changes and mortality at 30-days. Baseline characteristics did not differ between groups. The proportion of patients who achieved a clinical scale NCT04387760. Registration date: 07/05/2020